News

In a Warning Letter to a manufacturer of non-sterile drugs, the FDA criticized, among other deficiencies, a lack of testing of the manufactured batches for microbiological quality in accordance with USP chapters <61> and <62>, which deal with the "Enumeration" test and the test for "Specified Microorganisms".

More

In 2022, the WHO published the "Technical Report Series 1044, 2022" called "TRS 1044 - Annex 4: WHO guidelines on technology transfer in pharmaceutical manufacturing" on the subject of technology transfer.

More

The GMP/GDP Inspectors Working Group decided at the end of 2023 to extend the validity of GDP and GMP certificates that expired at the end of the year until 2024 or until the next on-site inspection, whichever occurs first. It has now been clarified that from 2025, this extension no longer applies.

More

In February 2025, the U.S. FDA issued a Warning Letter to the Indian company "Tyche Industries Ltd" due to insufficient Documentation Practices.

More

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to an American contract testing laboratory, emphasizing that it considers contractors as extensions of the manufacturer’s own facility. The authority identified critical deficiencies, including the failure to validate microbiological testing methods in accordance with USP standards and inadequate investigation of temperature and humidity deviations in laboratory equipment.

More

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter highlighting significant deviations from Current Good Manufacturing Practice (CGMP) for Active Pharmaceutical Ingredients (APIs). A facility in China was found to have multiple compliance deficiencies based on a review of records submitted in response to an FDA request.

More

In January 2025, the U.S. FDA issued a Warning Letter on its webpage due to the lack of evaluation of impurities - also during the stability studies.

More

The Swiss Medicines Agency Swissmedic and Health Canada have agreed to expand their approach to implementing the current MRA. More inspections will now be recognised.

More

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter following an inspection conducted in September 2025. The contract testing laboratory in question analyzed active pharmaceutical ingredients (APIs) and intermediates for compliance with regulatory standards for the U.S. market.

More

In January 2025, the Task Force "Data Integrity" of the Quality Group of APIC, a sector group of the European Chemical Industry Council (CEFIC), published version 2 of the document "Data Integrity Frequently Asked Questions (FAQ)" on its website. Updated and new questions and answers can be found in the "Password management" and "Access management" sections.

More
x
Search